Better prognosis among long-term responders treated with Tolvaptan for cirrhosis

In decompensated liver cirrhosis, long-term responders with water retention treated with tolvaptan without recurrence experienced significantly better prognosis, according to study results.“Our data also suggested that obtaining a long-term response without recurrence might be important for achieving a good prognosis,” Masato Nakai, MD, from the department of gastroenterology and hepatology at Hokkaido University Graduate School of Medicine in Japan, said. “In the treatment of decompensated cirrhosis with water retention, the addition of treatments that control inflammation,Read More